New once-daily formulation for trospium in overactive bladder
Author:
- 15 September 2010
- journal article
- review article
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 64 (11) , 1535-1540
Abstract
AIMS We examined the relative efficacy and safety of trospium 20 mg bid and 60 mg extended release formulations and position this drug against other antimuscarinic agents. Data were identified on the pharmacology and pharmacokinetics of trospium chloride. Key publications on trospium 20-mg and 60-mg clinical studies in patients with overactive bladder (OAB) were identified and efficacy and safety compared between these formulations as well as other antimuscarinic agents. Trospium offers the principal advantage over other antimuscarinic agents that, as it is a quaternary amine, it does not cross the blood-brain barrier and is therefore less likely to cause central nervous system effects observed with several other agents. Moreover, with its minimal liver metabolisation, independent of the main cytochrome pathways, trospium has a low risk of drug-drug interaction in patients taking multiple pharmacological agents. Trospium 60 mg ER is as effective as trospium 20 mg bid in improving the key outcome parameters associated with OAB, but with a lower rate of dry mouth, the most common side effect of these agents. Trospium has comparable efficacy and safety to the other antimuscarinic agents currently marketed. Good patient persistence with treatment has been reported with trospium. There are currently a large number of antimuscarinic drugs on the market without clear evidence to distinguish one agent from another in terms of efficacy, provided that an adequate dose is used in the clinical setting. The new formulation of trospium is certainly worth considering as a pharmacological treatment of patients with OAB, particularly in the elderly, in whom one wants to avoid the potential for cognitive dysfunction.Keywords
This publication has 27 references indexed in Scilit:
- Pharmacokinetics of Once‐Daily Trospium Chloride 60 mg Extended Release and Twice‐Daily Trospium Chloride 20 mg in Healthy AdultsThe Journal of Clinical Pharmacology, 2010
- Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacinInternational Journal Of Clinical Practice, 2008
- Trospium Chloride: Distinct Among Other Anticholinergic Agents Available for the Treatment of Overactive BladderUrologic Clinics of North America, 2006
- Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladderBritish Journal of Pharmacology, 2006
- Antimuscarinic Drugs for Overactive Bladder and Their Potential Effects on Cognitive Function in Older PatientsJournal of the American Geriatrics Society, 2005
- TROSPIUM CHLORIDE IMPROVES OVERACTIVE BLADDER SYMPTOMS: A MULTICENTER PHASE III TRIALJournal of Urology, 2004
- Management of Overactive BladderNew England Journal of Medicine, 2004
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- The minor population of M3‐receptors mediate contraction of human detrusor muscle in vitroJournal of Autonomic Pharmacology, 2001
- Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteersEuropean Journal of Clinical Pharmacology, 1994